NCT05718791 CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
| NCT ID | NCT05718791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henry Ford Health System |
| Condition | GVHD,Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-05-10 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-05-10 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Eligibility Criteria
Inclusion Criteria: * Patients \>18 year old admitted for allo SCT PB for malignant disease.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05718791 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying GVHD,Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05718791 currently recruiting?
Yes, NCT05718791 is actively recruiting participants. Contact the research team at sfarhan1@hfhs.org for enrollment information.
Where is the NCT05718791 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT05718791 clinical trial?
NCT05718791 is sponsored by Henry Ford Health System. The trial plans to enroll 100 participants.